Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

EHEC-HUS consortium, Jan Menne, Martin Nitschke, Robert Stingele, Mariam Abu-Tair, Jan Beneke, Jörn Bramstedt, Jan P Bremer, Reinhard Brunkhorst, Veit Busch, Reinhard Dengler, Günther Deuschl, Klaus Fellermann, Helmut Fickenscher, Christoph Gerigk, Alexander Goettsche, Jobst Greeve, Carsten Hafer, Friedrich Hagenmüller, Hermann HallerStefan Herget-Rosenthal, Bernd Hertenstein, Christina Hofmann, Melanie Lang, Jan T Kielstein, Ulrich C Klostermeier, Johannes Knobloch, Markus Kuehbacher, Ulrich Kunzendorf, Hendrik Lehnert, Michael P Manns, Tobias F Menne, Tobias N Meyer, Claus Michael, Thomas Münte, Christine Neumann-Grutzeck, Jens Nuernberger, Hermann Pavenstaedt, Leyla Ramazan, Lutz Renders, Jonas Repenthin, Wolfgang Ries, Axel Rohr, Lars Christian Rump, Ola Samuelsson, Friedhelm Sayk, Bernhard M W Schmidt, Sabine Schnatter, Harald Schöcklmann, Jürgen Steinhoff, Jürgen Büning


OBJECTIVE: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.

DESIGN: Multicentre retrospective case-control study.

SETTING: 23 hospitals in northern Germany.

PARTICIPANTS: 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome.

MAIN OUTCOME MEASURES: Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death.

RESULTS: 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P = 0.03), fewer deaths (0% v 5%, p = 0.029), required no abdominal surgery, and excreted E coli for a shorter duration.

CONCLUSIONS: Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.

Original languageEnglish
JournalBMJ (Online)
Pages (from-to)e4565
Publication statusPublished - 19.07.2012


Dive into the research topics of 'Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study'. Together they form a unique fingerprint.

Cite this